JP7229565B2 - メラノーマを治療するための方法 - Google Patents

メラノーマを治療するための方法 Download PDF

Info

Publication number
JP7229565B2
JP7229565B2 JP2020550082A JP2020550082A JP7229565B2 JP 7229565 B2 JP7229565 B2 JP 7229565B2 JP 2020550082 A JP2020550082 A JP 2020550082A JP 2020550082 A JP2020550082 A JP 2020550082A JP 7229565 B2 JP7229565 B2 JP 7229565B2
Authority
JP
Japan
Prior art keywords
melanoma
tumor
cells
dapanthril
olt1177
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020550082A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021518374A5 (https=
JP2021518374A (ja
JPWO2019182981A5 (https=
Inventor
マーチェッティ カルロ
エー．ディナレロ チャールズ
Original Assignee
オラテック セラピューティクス リミティド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オラテック セラピューティクス リミティド ライアビリティ カンパニー filed Critical オラテック セラピューティクス リミティド ライアビリティ カンパニー
Publication of JP2021518374A publication Critical patent/JP2021518374A/ja
Publication of JP2021518374A5 publication Critical patent/JP2021518374A5/ja
Publication of JPWO2019182981A5 publication Critical patent/JPWO2019182981A5/ja
Application granted granted Critical
Publication of JP7229565B2 publication Critical patent/JP7229565B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020550082A 2018-03-21 2019-03-18 メラノーマを治療するための方法 Active JP7229565B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862645999P 2018-03-21 2018-03-21
US62/645,999 2018-03-21
PCT/US2019/022770 WO2019182981A1 (en) 2018-03-21 2019-03-18 Methods for treating melanoma

Publications (4)

Publication Number Publication Date
JP2021518374A JP2021518374A (ja) 2021-08-02
JP2021518374A5 JP2021518374A5 (https=) 2022-03-15
JPWO2019182981A5 JPWO2019182981A5 (https=) 2022-03-15
JP7229565B2 true JP7229565B2 (ja) 2023-02-28

Family

ID=67987925

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020550082A Active JP7229565B2 (ja) 2018-03-21 2019-03-18 メラノーマを治療するための方法

Country Status (7)

Country Link
US (1) US11857529B2 (https=)
EP (1) EP3768384B1 (https=)
JP (1) JP7229565B2 (https=)
CN (1) CN111867678B (https=)
CA (1) CA3094307A1 (https=)
MX (1) MX2020009552A (https=)
WO (1) WO2019182981A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12121565B2 (en) * 2019-09-13 2024-10-22 Duke University Methods of treatment of specific cancers with NLRP3 inhibitors and anti-PD1/PD-L1 antibodies
WO2021076444A1 (en) 2019-10-14 2021-04-22 Olatec Therapeutics Llc Methods for treating breast cancer
JP2024534040A (ja) * 2021-08-19 2024-09-18 オラテック セラピューティクス， インコーポレイティド パーキンソン病の治療方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016176504A1 (en) 2015-04-28 2016-11-03 Bristol-Myers Squibb Company Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
JP2020503358A (ja) 2017-01-06 2020-01-30 オラテック セラピューティクス リミティド ライアビリティ カンパニー 心血管疾患を治療する方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013006708A (es) * 2010-12-15 2013-09-13 Olatec Ind Llc Composicion de 3-metanosulfonilpropionitrilo para el tratamiento de la inflamacion y el dolor.
CA2875052C (en) * 2012-06-05 2020-07-14 Olatec Industries Llc Method for treating skin inflammatory diseases
CN104334165B (zh) * 2012-06-05 2017-09-05 欧拉泰克工业有限责任公司 用于治疗炎症和疼痛的药物组合物
SI3259253T1 (sl) * 2015-02-16 2020-07-31 The University Of Queensland Sulfonilsečnine in sorodne spojine ter njihova uporaba
CA3021349A1 (en) * 2016-04-19 2017-10-26 Innate Tumor Immunity, Inc. Nlrp3 modulators
NL2017267B1 (en) * 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
WO2018129231A1 (en) * 2017-01-06 2018-07-12 Olatec Therapeutics Llc Method for treating multiple sclerosis
WO2018204764A1 (en) 2017-05-05 2018-11-08 Camp4 Therapeutics Corporation Identification and targeted modulation of gene signaling networks
WO2019152627A1 (en) * 2018-01-31 2019-08-08 Olatec Therapeutics Llc Method for preventing or treating alzheimer's disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016176504A1 (en) 2015-04-28 2016-11-03 Bristol-Myers Squibb Company Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
JP2020503358A (ja) 2017-01-06 2020-01-30 オラテック セラピューティクス リミティド ライアビリティ カンパニー 心血管疾患を治療する方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Proceeding of the National Academy of Sciences of the United States of America，2018年01月29日，Vol.115, No.7，p.E1530-E1539
Toxicology and Applied Pharmacology，2013年，Vol.279, No.1，p.70-76

Also Published As

Publication number Publication date
US11857529B2 (en) 2024-01-02
CN111867678B (zh) 2023-04-28
CA3094307A1 (en) 2019-09-26
WO2019182981A1 (en) 2019-09-26
EP3768384A1 (en) 2021-01-27
US20200405681A1 (en) 2020-12-31
MX2020009552A (es) 2020-10-05
EP3768384A4 (en) 2021-11-17
JP2021518374A (ja) 2021-08-02
EP3768384B1 (en) 2025-06-25
CN111867678A (zh) 2020-10-30

Similar Documents

Publication Publication Date Title
JP7671327B2 (ja) 消化管間質腫瘍の治療のための併用療法
US20130129675A1 (en) Interferon therapies in combination with blockade of stat3 activation
BR112019024135A2 (pt) Terapias de combinação para o tratamento de câncer
Foletto et al. Cutaneous melanoma: new advances in treatment
JP7229565B2 (ja) メラノーマを治療するための方法
KR20180094989A (ko) 노화 관련 인지장애 및 신경염증의 예방 및/또는 치료 방법
Pavia et al. Generalized pustular psoriasis flare in a patient affected by plaque psoriasis after BNT162b2 mRNA COVID‐19 vaccine, successfully treated with risankizumab
CN108139403A (zh) 用于组合疗法的患者的选择
WO2018083704A1 (en) Use of hexokinase 2/mitochondria-detaching compounds for activating immune responses
JP2011506436A (ja) 細胞傷害性ｔリンパ球抗原４（ｃｔｌａ４）に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法
US11517575B2 (en) Use of minaprine to reduce tumor growth
US12582628B2 (en) Methods for treating breast cancer
KR101978108B1 (ko) 암 세포의 대사 특이성에 기초하는 신규 항 악성 종양제
KR20090020646A (ko) 4기 악성 흑색종의 치료를 위한 약제의 제조를 위한 티모신알파 1의 용도
EP3664786B1 (en) Method for treating schnitzler's syndrome
Donskov et al. Outpatient treatment with subcutaneous histamine dihydrochloride in combination with interleukin-2 and interferon-α in patients with metastatic renal cell carcinoma: results of an open single-armed multicentre phase II study
JP7648155B2 (ja) プロカスパーゼ‐３の活性化及びがんの治療のための免疫療法
US20240417812A1 (en) Methods for treating solid cancer patients with clonal hematopoiesis of indeterminate potential
JP7303827B2 (ja) 腫瘍増殖を抑制するためのミナプリンの使用
Madleen et al. Metabolic and immunological phenotype of rare lipomatoses: Dercum’s disease and Roch-Leri mesosomatic lipomatosis
Keshavarz et al. Multi-tyrosine kinase inhibitors: exploring immunomodulatory effects on various immune cell types in cancer
Sakr et al. Modulation of proinflammatory cytokines and leukocyte mobilization by melatonin in response to sterile tissue injury in Wistar albino rats
Fromer Metastatic Kidney Cancer: Prognosis Still Poor, But New Treatment Options on Horizon

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220307

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220307

TRDD Decision of grant or rejection written
A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221223

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230110

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230208

R150 Certificate of patent or registration of utility model

Ref document number: 7229565

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250